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Abstract: HIV-1 protease is one of the major antiviral targets in the treatment of patients 
infected with HIV-1. The nine FDA approved HIV-1 protease inhibitors were developed 
with  extensive  use  of  structure-based  drug  design,  thus  the  atomic  details  of  how  the 
inhibitors bind are well characterized. From this structural understanding the molecular 
basis  for  drug  resistance  in  HIV-1  protease  can  be  elucidated.  Selected  mutations  in 
response to therapy and diversity between clades in HIV-1 protease have altered the shape 
of the active site, potentially altered the dynamics and even altered the sequence of the 
cleavage sites in the Gag polyprotein. All of these interdependent changes act in synergy to 
confer  drug  resistance  while  simultaneously  maintaining  the  fitness  of  the  virus.  New 
strategies,  such  as  incorporation  of  the  substrate  envelope  constraint  to  design  robust 
inhibitors that incorporate details of HIV-1 protease’s function and decrease the probability 
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of drug resistance, are necessary to continue to effectively target this key protein in HIV-1 
life cycle. 
Keywords:  drug  resistance;  HIV-1  protease;  protease  inhibitors;  substrate  envelope; 
structure based drug design 
 
1. Introduction  
According to the recent reports published by UNAIDS, there are about 33.4 million people living 
with HIV-AIDS around the globe [1]. Currently, there is no permanent cure or vaccine for AIDS but 
there are about 25 drugs that belong to seven classes targeting different stages in the life cycle of 
HIV [2]. Although the quality and life expectancy of HIV infected patients has improved since the 
introduction of antiviral treatment, low drug adherence, toxicity, and high pill burden, coupled with the 
error prone mechanism of HIV reverse transcriptase, have led to the emergence of drug resistance in 
HIV infected patients (for recent reviews see [2–5]). 
Protease inhibitors (PIs) are one class of drugs that target an essential viral enzyme HIV-1 protease. 
Because of its critical role in the processing of Gag and Gag-Pro-Pol polyproteins into individual 
proteins  necessary  for  viral  maturation  [6],  protease  is  one  of  the  major  therapeutic  targets  for 
developing antiviral drugs against HIV-AIDS. In the last two decades, drug discovery efforts aided by 
structure-based design have led to the development of nine FDA-approved protease inhibitors (PIs) 
(Figure 1): Saquinavir (SQV) [7], Indinavir (IDV) [8], Ritonavir (RTV) [9], Nelfinavir (NFV) [10], 
Amprenavir (APV) [11], Lopinavir (LPV) [12], Atazanavir (ATV) [13], Tipranavir (TPV) [14], and 
Darunavir (DRV) [15–17]. These inhibitors represent the most potent anti-AIDS drugs reported to date 
and are essential components of the highly active antiretroviral therapy (HAART) [18,19]. HAART is 
credited  with  significantly  reducing  AIDS-related  mortality  [20,21]  and  is  currently  implemented 
throughout the world as the standard of care for HIV-AIDS treatment. 
Drug resistance to PIs has become a major issue with the failure of HAART. Moreover, newly 
infected patients are infected with resistant viruses which are an added challenge in the treatment of 
HIV  infections.  Various  strategies  have  been  used  to  develop  new  antiviral  therapies  against 
drug-resistant  HIV,  including  increasing  the  plasma  levels  of  existing  PIs  by  using  a  boosting 
agent [22]  and  developing  new  PIs  using  structure-based  drug  design  [4,23–25].  Among  different 
approaches, one design strategy maximizes the number of hydrogen bonds with the protease backbone 
and led to the development of highly potent PIs active against drug-resistant HIV [25,26]. PIs with 
improved  resistance  profiles  were  also  developed  using  a  solvent  anchoring  approach  [27],  and 
utilizing a new lysine sulfonamide-based molecular core [28]. Another design strategy incorporates 
substrate envelope constraints into structure-based design and led to the discovery of novel highly 
potent PIs that are less susceptible to drug-resistance [29]. The principles underlying these various 
strategies are not necessarily mutually exclusive and all achieved the design of highly potent inhibitors 
against drug-resistant HIV. 
   Viruses 2010, 2                         
 
 
2511 
Figure 1. FDA-approved HIV-1 protease inhibitors. 
 
 
2. FDA-approved HIV-1 Protease Inhibitors 
All currently approved HIV-1 PIs are competitive active site inhibitors that bind in the active site of 
the protease and, except for TPV, all are peptidomimetics. These PIs were rationally designed based on 
the  transition  state  mimetic  concept  and  contain  various  non-cleavable  dipeptide  isosteres  as  core 
scaffolds to mimic the transition state of the polyprotein substrates of HIV-1 protease (Figure 2). A key 
common feature of these inhibitors is the presence of a secondary hydroxyl group, a surrogate for the 
P1  carbonyl  moiety  of  substrates,  which  makes  critical  interactions  with  the  catalytic  Asp25/25′ 
residues of the protease and is required for tight inhibitor binding with the protease. Another common 
feature in the complexes between peptidomimetic inhibitors and HIV-1 protease is a conserved water 
molecule that mediates contacts between the P2/P1′ carbonyl oxygen atoms of the inhibitors and the 
amide groups of Ile50/Ile50′ of the enzyme. The development and clinical introduction of HIV-1 PIs is 
regarded as a major success of structure-based rational drug design [30]. 
Development of the first generation PIs was greatly facilitated by the knowledge of inhibitors of 
other aspartic proteases such as renin, and early availability of numerous crystal structures of both 
unliganded enzyme and enzyme-ligand complexes [30–32]. Initial designs of inhibitors were based on 
pepstatin, a natural transition state mimic, and sequence homology of substrate cleavage sites at the 
Gag and Gag-Pro-Pol polyprotein containing a non-cleavable reduced amide dipeptide isostere [33]. 
The crystal structures of these early inhibitor-protease complexes provided a wealth of information on Viruses 2010, 2                         
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the inhibitor-enzyme interactions in the protease active site and led to the optimization of various 
lead inhibitors. 
SQV, discovered by Roche [7], was the first HIV-1 PI approved by the FDA in December 1995 for 
the  treatment  of  HIV-AIDS.  The  initial  pentapeptide  lead  was  based  on  the  HIV-1  pol  substrate 
sequence containing the unusual Phe-Pro amide bond at the cleavage site. Lead optimization, including 
replacement  of  the  P1-P1′  amide  bond  with  non-cleavable  hydroxyethylamine  (Figure  2-I)  based 
dipeptide  isostere,  replacement  of  the  P1′  proline  with  a  bicyclic  decahydroisoquinoline,  and 
introduction of a quinoline moiety at P3 led to the discovery of SQV. Although SQV is a very potent 
(Ki = 0.12 nM) and selective inhibitor of HIV-1 protease, SQV has very poor bioavailability and is 
quickly degraded in vivo by cytochrome P450 (CYP-450).  
Figure 2. The scissile bond in polyprotein substrate is hydrolyzed by protease through the 
transition state intermediate (substrate amino acid residues are marked as...P3, P2, P1, P1′, 
P2′, P3′…and the corresponding enzyme binding sites as…S3, S2, S1, S1′, S2′, S3′…). 
Transition state mimics I–V used in the design of currently approved drugs.  
 
 
SQV was soon followed by two structurally distinct PIs, IDV [8] and RTV [9]. IDV, developed by 
Merck, was also optimized from an initial peptide lead in which the P1-P1′ fragment was replaced 
with a novel Phe-Gly hydroxyaminopentane dipeptide isostere (Figure 2-II). The other key structural 
features  of  IDV  are  the  aminohydroxyindane  moiety  at  P2′  position  and  a  P1-P2 
pyridylmethylpiperazine moiety. IDV has protease inhibitory potency of 0.6 nM, antiviral potency 
of 25–100 nM, and has excellent oral bioavailability. 
In the discovery of RTV, the Abbott team sought to exploit the C2 symmetry of the HIV-1 protease 
and initially designed inhibitors by incorporating a C2 symmetric dihydroxy Phe-Phe isostere core. 
During the lead optimization process, they discovered that the second hydroxyl  group  in the core 
isostere  could  be  removed  without  affecting  the  potency  leading  to  the  development  of  a 
pseudo-symmetric  all  carbon  Phe-Phe  hydroxyethylene  isostere  core  (Figure  2-III).  RTV  potently 
inhibits HIV-1 protease (Ki = 0.022 nM) and has moderate antiviral potency (EC50 = 60 nM). Due to 
its numerous side effects RTV is no longer used as a PI on its own. However, RTV is a potent inhibitor Viruses 2010, 2                         
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of CYP-450 3A4 isoform [34], and, because of this side activity, low dose RTV is currently used as a 
boosting agent in HAART therapy with other PIs.  
NFV  [10]  was  developed  by  truncating  the  N-terminal  moiety  in  SQV  and  replacing  the  P2 
asparagine with 3-hydroxy-2-methylbenzamide fragment. These changes in combination with a novel 
P1 moiety in  the hydroxyethylamine isostere led to  NFV (Ki  = 2 nM) with  significantly  reduced 
molecular weight and improvement in bioavailability, though NFV is less potent than SQV. Efforts by 
Vertex aimed at reducing the molecular weight and peptide character of PIs led to the discovery of 
APV [11], which incorporates a novel hydroxyethylamino-sulfonamide dipeptide isostere (Figure 2-IV). 
The 3-hydroxyltetrahydrofuran P2 moiety was designed to mimic the interactions of SQV’s asparagine 
side chain with the Asp29 residue. APV, also approved as a prodrug (fosamprenavir), is the smallest of 
the 9 currently approved PIs; APV has moderate potency (Ki = 0.6 nM), good bioavailability and long 
half-life, allowing twice daily dosing in patients.  
Based  on  the  first  generation  PI  RTV,  Abbott  developed  a  highly  potent  second  generation 
inhibitor, LPV [12], which is also active against RTV-resistant protease variants. Significant efforts 
directed at replacing the bulky (2-isopropylthiazolyl)methyl P3′ moiety with smaller groups led to the 
discovery of cyclic urea as a high affinity P3′ moiety. The P2 thiazolylmethyl moiety was also replaced 
with  a  more  lipophilic  2-(2,6-dimethylphenoxy)acetamide  resulting  in  an  exceedingly  potent  PI 
with 10-fold better potency than RTV. Although LPV has poor bioavailability and pharmacokinetic 
profile, its plasma levels could be significantly enhanced by adding low dose RTV [22]; a combination 
of LPV/RTV (Kaletra) is one of the most widely used PI therapies. 
ATV  [13],  approved  in  2003,  incorporates  a  novel  (hydroxyethyl)hydrazine  or 
aza-hydroxyethylamine  dipeptide  isostere  (Figure  2-V),  an  extended  4-(2-pyridinyl)phenylmethyl 
moiety  and  a  methylcarbamate  capped  tert-leucine  moiety  at  both  P2/P3  and  P2′/P3′  positions. 
Compared to the hydroxyethylene core of LPV, the P1-P2 aza-linkage eliminates one of the three 
chiral  centers  allowing  easier  large-scale  synthesis.  ATV  has  high  antiviral  potency  and  oral 
bioavailability, and is the only PI that allows once daily dosing. 
TPV [14] is the only non-peptidomimetic PI developed from lead compounds 4-hydroxycoumarin 
and 4-hydroxy-2-pyranone, identified by high throughput screening. Unlike other PIs, TPV is not a 
transition state mimetic, and instead binds to the protease in a distinct fashion replacing the conserved 
flap water. The phenolic hydroxyl group of the central 4-hydroxy-2-pyranone moiety makes hydrogen 
bond interactions with the Asp25/25’ in the floor of the active site and the carbonyl group, unlike 
peptidomimetic inhibitors, makes direct hydrogen bond interactions with Ile50/50’ in the flap region of 
the protease. TPV potently inhibits multidrug-resistance protease variants and the replication of viruses 
that are resistant to most other PIs. TPV, due to its unique binding mode with the protease, a resistance 
profile different from other drugs, and a higher barrier to resistance requiring multiple mutations, is 
recommended for therapy with patients containing preexisting protease resistance.  
DRV  [15–17],  the  latest  protease  inhibitor  approved  by  the  FDA,  incorporates  the  same 
hydroxyethylamino-sulfonamdie isostere present in APV. In fact, both compounds are very similar 
with the only difference being a condensed bis-tetrahydrofuranyl (bis-THF) moiety at P2 present in 
darunavir instead of a single tetrahydrofuranyl (THF) ring of APV. DRV was developed by both 
academic and industrial research efforts based on the crystal structures of HIV-1 protease bound to 
APV, SQV and its analogues bearing the bis-THF moiety at P2 position. These crystal structures Viruses 2010, 2                         
 
 
2514 
revealed  that  the  oxygen  atoms  of  the  THF/bis-THF  moieties  make  extensive  hydrogen  bond 
interactions with the Asp29/Asp30 residues of the protease enzyme. The critical interactions of the 
bis-THF  moiety  in  the  S2  binding  pocket  of  the  protease  enzyme  are  largely  responsible  for  the 
exceptionally high inhibitory and antiviral potency of darunavir (Ki = 15 pM; EC50 = 1–4 nM). DRV is 
the most potent antiviral protease inhibitor approved to date and is also highly effective against most of 
the multi-drug resistant HIV-1 variants. 
The enzyme inhibitory activities of all FDA approved HIV PIs against wild-type (WT) protease and 
three drug-resistant variants and their cellular antiviral potencies against wild-type HIV are provided in 
Table 1 for comparison. The first generation PIs, RTV, SQV, IDV, NFV, lose significant activity 
against drug-resistant protease variants, however, recently approved drugs TPV and DRV retain low 
picomolar (pM) inhibitory activities. 
Table  1.  Binding  affinity  [29,35]  and  antiviral  potency  [36]  of  FDA  approved  HIV-1 
protease inhibitors. 
Inhibitor 
Ki (nM) 
Antiviral 
EC50 (nM)  WT/Q7K 
L10I, G48V, 
I54V, L63P, 
V82A 
D30N, 
L63P, N88D 
L10I, L63P, 
A71V, G73S, 
I84V, L90M 
Saquinavir  0.065  90  1.0  78  26 
Indinavir  0.18  34  0.73  21  40 
Ritonavir  0.055  3.0  0.46  2.8  65 
Nelfinavir  0.28  15  3.5  19  71 
Amprenavir  0.10  0.15  0.21  1.40  44 
Lopinavir  0.005  6.1  0.04  0.90  10 
Atazanavir  0.046  0.33  0.009  0.49  15 
Tipranavir  0.088  0.014  0.001  0.032  500 
Darunavir  0.008  0.005  0.041  0.025  1 
 
3. Interdependency of Drug Resistance 
3.1. Substrate Envelope Hypotheses  
Within  the  Gag  and  Gag-Pro-Pol,  HIV-1  protease  cleavage  sites  are  non-homologous  and 
asymmetric, both in charge and size. These characteristics begged the question as to how a symmetric 
protease could recognize and cleave an asymmetric substrate. Structural studies have shown that the 
various cleavage site peptides adopt a conserved shape/volume, which was hypothesized as the basis 
for recognition of substrate sites by the HIV-1 protease [37]. This overlapping volume of the majority 
of the substrates within the active site of the protease defines the conserved shape or the “substrate 
envelope” (Figure 3A). The P1-P3 region of the substrates forms a toroid, which is thought to be 
important for specificity, whereas the numerous backbone-to-backbone interactions of the protease and 
the  substrates  facilitate  binding  [37].  The  substrate  envelope  not  only  explains  specificity  of  the 
substrates but also the development of resistance to various PIs and substrate co-evolution [38]. 
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Figure  3.  (A)  Substrate  envelope  of  HIV  protease.  PyMOL  model  generated  from 
overlapping  van  der  Waals  volume  of  substrate  peptides.  Red:  matrix  capsid,  green: 
capsid-p2,  blue:  p2-nucleocapsid,  cyan:  p1-p6,  magenta:  reverse  transcriptase-
ribonucleaseH, yellow: ribnucleaseH-integrase. (B) The inhibitor envelope in red, within 
the active site of HIV-1 protease, calculated from overlapping van der Waals volume of 
five or more of eight inhibitor complexes. (C) Superimposition of the substrate consensus 
volume (blue) with the inhibitor consensus volume (red). Residues that contact with the 
inhibitors  where  the  inhibitors  extend  beyond  the  substrate  volume  and  confer  drug 
resistance when they mutate are labeled (Figures 3A-C, modified from King et al. [38]). 
A 
 
B 
 
C 
 
 
Crystallographic studies of the wild-type protease bound to inhibitor molecules have shown that 
most of the PIs occupy a similar volume (defined as the inhibitor envelope, Figure 3B) and contact Viruses 2010, 2                         
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similar residues within the active site of the protease. Drug resistance occurs where inhibitor atoms 
protrude  beyond  the  substrate  envelope  and  contact  protease  residues  (Figure  3C)  [38].  Thus, 
mutations at these sites would specifically impact inhibitor binding while substrate recognition and 
cleavage remains relatively unaffected. The fact that most of the sites of drug resistant mutations in the 
active site do not contact the substrates led to the development of the substrate envelope hypothesis: 
Inhibitors that fit well within the substrate envelope would be less susceptible to drug resistance, as a 
mutation that affects inhibitor binding would simultaneously impact the recognition and processing of 
the majority of the substrates [38]. Of the currently prescribed inhibitors the most efficacious is DRV 
and  although  not  designed  using  the  substrate  envelope  constraint,  DRV  fits  well  within  this 
volume [39,40].  These  studies  also  suggested  that  if  the  substrate  atoms  that  protrude  out  of  the 
substrate envelope contact the very same residues in the active site of the protease that mutate to 
prevent inhibitor binding, it could lead to impaired substrate recognition and cleavage resulting in the 
co-evolution of compensatory mutations within the protease cleavage sites [38]. 
3.2. Drug Resistance—A Change in Molecular Recognition at the Active Site 
The development of drug resistance is a major factor for the failure of protease inhibitor therapy. 
The virus evolves to accumulate a multitude of mutations within the protease that prevent PIs from 
binding  to  the  protease.  More  than  half  the  residues  within  the  protease  mutate  in  different 
combinations and lead to drug resistance [41,42]. Drug resistance is a subtle change in the balance of 
recognition events: The protease is still able to recognize and process the natural substrate sites in the 
Gag and Gag-Pro-Pol polyprotein, while no longer being effectively inhibited by competitive drug 
molecules. This hints that as drug resistance emerges, the interactions of the protease with an inhibitor 
should significantly be altered to facilitate the reduced affinity of the protease to the inhibitors while 
the interactions with a natural substrate should be maintained as in the wild-type structures. 
As the functional HIV-1 protease is a symmetric dimer, both monomers contribute to substrate 
binding. The active site region is primarily formed by residues 25–32, 47–53 and 80–84. Mutations 
occurring anywhere else in the protease are referred to as the non-active site mutations. 
Under protease inhibitor therapy, a majority of initial mutations arise within the active site of the 
enzyme, directly affecting inhibitor binding and are the primary cause of resistance to PIs. Typical 
primary mutations include D30N, G48V, I50L/V, V82A/F/T, I84V and L90M [43]. Several primary PI 
resistance mutations have been described that are a signature of particular PIs. For example, patients 
failing NFV therapy develop the D30N protease mutation [44], while the I50V and I50L mutations are 
selected in patients failing APV/DRV and ATV therapy, respectively [45,46]. Mutations at protease 
residue 82 are observed in patients treated with RTV and SQV, and the G48V mutation results in 
resistance  to  SQV  and  ATV  [47,48].  The  I84V  mutation  is  one  of  the  severe  primary  resistance 
mutations causing cross-resistance to most PIs [49]. Thus, a range of primary resistance mutations are 
selected, some of which are unique to a single PI, whereas others confer resistance to two or more PIs. 
Mutations  in  HIV-1 protease, either within or outside the active site, can decrease the binding 
affinity of inhibitor molecules in a complex, interdependent and cooperative manner. When a protease 
variant binds to an inhibitor, the structure of the protease adjusts to accommodate the inhibitor by 
rearranging the interactions not only at the mutated residue but also throughout the protein [50–52]. Viruses 2010, 2                         
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Analysis of protease inhibitor complexes has shown that the structure of HIV protease is highly 
plastic [4,35,51]. The conformational change observed in the mutant protease is not always just around 
the  vicinity  of  the  mutation.  Various  conformations  found  in  crystal  structures  are  probably  the 
combined effect of the nature of the inhibitor and the combination of mutations present in the protease. 
Whether there is a major conformational change in the protease backbone or not, the drug resistant 
mutation(s) does have an impact on the binding affinity to the inhibitor. 
The rearrangement of the backbone can be observed either in the entire protease or in some parts of 
the protease, as in flap region or P1 loop region, or just locally around the mutated residue [53]. 
Previous studies involving the drug resistant inactive variant of protease (D25N and V82A) with the 
inhibitors SQV and RTV showed that the binding of the inhibitor is compromised because of the drug 
resistant mutation, V82A [51]. In addition to the direct loss of van der Waals contacts between the 
inhibitors and the protease as a result of the V82A mutation, the mutant protease also undergoes 
conformational changes as observed by the large shifts in the Cα backbone compared to the wild-type 
structure. In another study [54], the binding of inhibitors, APV, DRV, ATV and SQV to the protease 
variant containing L10I, G48V, I54V and V82A mutations has shown large changes in the flap regions 
of the protease. In this case, the changes in the flap region are attributed to the two mutations present in 
the flap (G48V and I54V), which may have locked the conformation of the flaps. The study by Munshi 
et al. [50] revealed that the 80’s loop is intrinsically flexible and that mutations in this loop are not 
necessary to result in conformational changes. Conformation of the P1 loops in the inhibitor-protease 
complex depends mainly upon the nature of the bound inhibitor and may be influenced by mutations in 
the protease [50]. This means that the rearrangement of the protease also depends on the relative shifts 
and tilts in the bound inhibitor. For instance, in the study [39] involving the V82T/I84V protease 
variant  bound  to  APV  and  DRV,  minor  changes  in  the  backbone  of  the  protease  were  observed 
compared to  the wild  type. The P1 loop  of only one monomer is  shifted in  the mutant structure 
corresponding to the shift and tilt of DRV whereas, P1 loops of both the monomers of the protease are 
shifted in the APV mutant protease structure corresponding to the shift and tilt of APV. Additionally, 
there are minor backbone rearrangements in the crystal structures of the V82T/I84V protease variant 
with ATV and SQV [54] where the shifts and tilts of the inhibitors account for the altered interactions 
and hence, to the reduced affinity of the inhibitor. In a study by Konvalinka et al. [55], the impaired 
binding of the inhibitor to the drug resistant protease is explained by a change in hydrogen bonding 
pattern due to a substantial shift of the aminophenyl moiety of DRV. 
3.3. Contribution of Protease Mutations outside the Active Site  
Structural analyses of inhibitor complexes have been useful in the elucidation of the mechanism by 
which active site mutations confer resistance to PIs [37,38,51,56]. Notably, the substrate envelope 
hypothesis has helped explain the change in molecular recognition in resistant protease, where the 
enzyme  evolves  to  resist  inhibitor  binding  but  continues  to  recognize  and  bind  its  natural 
substrates [37]. However, the protease mutates extensively in the regions beyond active site, and these 
non-active site mutations have been known to greatly contribute to drug resistance. The mechanism by 
which the mutations outside the active site confer resistance remains elusive. Some of these mutations Viruses 2010, 2                         
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are primary drug resistant mutations and others have been suggested to contribute to drug resistance 
when present along with other major mutations. 
Of  the  99  positions  in  each  monomer,  nearly  37  are  known  to  be  invariant  (with  mutation 
frequencies <0.5%) and 17 positions are sites of non-treatment  related polymorphisms [41,42,57]. 
Nearly 45 positions in each monomer have been implicated in drug resistance. Of these 45 positions, 
mutations at 26 positions have been shown to significantly decrease susceptibility to one or more PIs 
and the others are polymorphic mutations that occur more frequently when associated with inhibitor 
therapy [42,58]. Furthermore, almost 60% of these 26 positions fall outside the active site region 
(Table  2).  Thus,  excluding  the  invariant  positions  and  including  the  polymorphic  sites  associated 
with drug  resistance,  almost  40–45%  of  the  protease  sequence  is  implicated  in  contributing  to 
drug resistance  [41,42,57],  and  a  staggering  60–63%  of  the  sequence  has  been  known  to  vary  in 
patient isolates. 
Table 2. The major non-active site mutation positions which cause decreased susceptibility 
to one or more PIs [22]. The known polymorphisms are listed for subtype B [40]. 
Positions 
Wild-type 
Amino Acid 
Most Frequent 
Mutations 
Polymorphic/ 
Non-polymorphic 
10  L  FI 
(L10I) Polymorphic 
(L10F) Non-polymorphic 
11  V  L  Non-polymorphic 
20  K  T  Non-polymorphic 
33  L  F  Non-polymorphic 
35  E  GN  Non-polymorphic 
43  K  T  Non-polymorphic 
46  M  IL  Non-polymorphic 
54  I  ALMSTV  Non-polymorphic 
58  Q  E  Non-polymorphic 
73  G  CST  Non-polymorphic 
74  T  PS  Non-polymorphic 
76  L  V  Non-polymorphic 
88  N  DS  Non-polymorphic 
89  L  V  Non-polymorphic 
90  L  M  Non-polymorphic 
 
Various  groups,  in  the  past,  have  studied  thermodynamic,  structural  and  kinetic  parameters  of 
various combinations of the major drug resistant mutations and contributory or associated non-active 
site secondary mutations in recombinant protease system [59–64]. Almost all these studies have shown 
that  the  effect  of  major  drug  resistance  mutations  is  highly  diminished  in  the  absence  of  paired 
secondary  non-active  site  mutations.  Although  the  mechanism  by  which  these  diversely  placed 
non-active  site  residues  orchestrate  altered  inhibitor-binding  remains  largely  unknown,  some 
residue-specific explanations and suggestions have been put forth [65,66]. One of the reasons for this 
altered binding has been suggested to lie in the internal dynamics and inherent plasticity of HIV-1 
protease [60,67,68]. Some of these mutations may induce conformational perturbations in the enzyme, Viruses 2010, 2                         
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altering binding of the inhibitors. Kinetic studies conducted on various permutations and combinations 
of active and non-active site protease mutants have shown that many of these protease variants have 
decreased catalytic efficiencies, resulting from either increased KM values or reduced turnover rates or 
a combination of both [60,69]. Some mutations, e.g., L90M, have been shown to make protease a 
better enzyme for one substrate over the other in a clade specific manner [52,70]. 
3.4. Impact of the Co-evolution of Protease Cleavage Sites on Resistance  
Following accumulation of resistance mutations within the protease, mutations also develop within 
the substrate cleavage sites in Gag and Gag-Pro-Pol [71,72]. Mutations were first reported within the 
NC-p1 and p1-p6 cleavage sites [71,73,74]. Additionally, associations between specific mutations in 
the protease and the cleavage sites have been reported previously, and were demonstrated to alter 
susceptibility to various PIs [71,73–76]. The A431V mutation within the NC-p1 cleavage site and 
L449F in the p1-p6 cleavage site selected during the evolution of PI  resistance were observed to 
correlate with V82A and I50V protease resistance mutations, respectively [71,76]. 
Gag  processing  is  enhanced  by  the  A431V  and  I437V  mutations  within  the  NC-p1  cleavage 
site [77,78]. In fact, there were clear structural changes that increased binding of the A431V NC-p1 
site with  the V82A protease  [79].  Recently though, both A431V  and  I437V have been shown to 
directly increase resistance, possibly as a result of this enhanced Gag processing [78,80]. Similarly, the 
L449F mutation within the p1-p6 cleavage site has been shown to increase processing at this cleavage 
site [76,77,81]. Likely, the change from a smaller amino acid to a larger Phe improves van der Waals 
contacts contributing improved Gag processing. These studies revealed that the p1-p6 cleavage site 
mutations are associated with the NFV-resistant D30N/N88D protease mutations. In addition to these, 
several other correlations between the NC-p1 and p1-p6 cleavage site mutations and primary drug 
resistant mutations were observed [82]. These cleavage site mutations have been demonstrated to be 
compensatory  in  nature  by  improving  replicative  capacity  and/or  Gag  processing  [77,79].  Other 
cleavage  site  mutations,  including  I437V  and  P453R,  have  now  been  well  documented  and  are 
associated with several major protease resistance mutations [76,82,83]. This suggests a mechanism 
whereby  decreased  interactions  between  cleavage  sites  and  mutant  protease  can  be  offset  by 
compensatory mutations within the cleavage sites leading to improved binding and processing. This 
implies that with prolonged PI therapy, evolution of protease cleavage sites could be a fairly frequent 
mechanism for maintaining viral fitness even as the virus evolves resistance to PIs. 
Studies  have  shown  that  co-evolution  of  substrate  cleavage  sites  and  protease  mutations  also 
contribute to PI resistance [78,82]. Primary PI resistance mutations, especially in the active site, reduce 
both protease catalytic efficiency and viral replicative capacity (RC) [84–87]. Several studies have 
demonstrated that the evolution of compensatory mutations within cleavage sites leads to improved 
viral  fitness  compensating  for  the  loss  in  fitness  resulting  from  the  protease  resistance 
mutations [71,72,74,88].  However,  significant  differences  were  not  observed  in  viral  fitness  with 
protease  resistance  mutations  in  the  presence  and  absence  of  mutations  within  the  Gag  cleavage  
sites [82]. More recently, Larrouy et al. observed that baseline cleavage site mutations, in treatment-
naïve patients, were significantly linked to virological outcomes [89]. More specifically, mutations at 
Gag 128 within the MA-CA and Gag 449 within the p1-p6
gag cleavage sites were associated with low Viruses 2010, 2                         
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virological response whereas mutations at Gag-Pol 437 within the TFP-p6
pol were frequent in patients 
achieving virological response [89]. In a recent study, Parry et al. demonstrated that mutations in the 
matrix and partial capsid in the N-terminal regions of Gag fully restore RC to WT levels and thus play 
a key role in fitness [90]. However, these mutations significantly enhanced resistance to PIs even in the 
absence of PI resistance mutations in the protease [90]. Thus, the evolution of mutations within the 
cleavage  sites  and  outside  play  an  important  role  in  the  development  of  resistance  and  affect 
virological response during therapy. 
Statistical  analysis  on  the  effect  of  the  observed  correlations  on  phenotypic  susceptibilities  to 
various PIs showed that these correlations were observed to significantly affect PI susceptibilities. In 
most  instances,  a  significant  decrease  in  phenotypic  susceptibility  to  particular  PIs  was  observed. 
Although mutations at either Gag 431 or Gag 437 were not associated with D30N/N88D protease 
mutations, significantly lower PI susceptibilities were observed. A similar trend was also observed 
with Gag A431V and the L90M protease mutation. Mutations at either of these residues within the 
NC-p1  cleavage  site  likely  directly  enhance  resistance  to  PIs,  as  was  observed  and  demonstrated 
previously [78,91]. At least in the case of the Gag A431V mutation, this is likely due to enhanced Gag 
processing  at  this  site  as  demonstrated  by  Nijhuis  et  al.  [80].  Thus,  Gag  cleavage  site  mutations 
enhance resistance to PIs in combination with primary drug resistance mutations in the protease. A 
detailed review of the role Gag cleavage sites on protease inhibitor resistance by Clavel and Mammano 
is included in this issue [92]. 
4. Altered Pathways to Drug Resistance between the HIV-1 Clades  
Based on genomic diversity, HIV-1 has been classified into nine clades (A, B, C, D, F, G, H, J,  
and K) and 43 circulating recombinant forms (CRFs) [93,94]. The protease amino acid sequences 
between clades vary up to about 10%. A number of these amino acid variations have been associated 
with PI resistance in clade B (Table 3). With the exception of clade G, which has an active site amino 
acid  substitution  when  compared  to  clade  B,  all  sequence  variations  within  other  clades  map  to 
positions outside the active site (Figure 4). While currently available PIs are effective against different 
HIV-1  clades  very  few  studies  have  been  carried  out  to  understand  the  effect  of  clade  specific 
sequence variations on the emergence of drug resistance. 
Despite the lack of data on pathways to resistance on non-B clade proteases, a number of studies 
focusing on sequence polymorphisms  in  protease have highlighted differences  in  biochemical  and 
structural  profiles  as  well  as  viral  replication  in  non-B  clade  viruses  when  compared  to  clade  B. 
Enzyme kinetics studies show higher KM values, 1.4-fold, for clade A and lower KM values, 2.6-fold 
and 3.4-fold, for clade C and G protease when compared to clade B and indicates that affinity for 
substrates might be different between clades [95]. Studies carried out on CRF01_AE have shown that 
while KM values were comparable to that of clade B the catalytic turnover rates (kcat) were significantly 
lower in CRF01_AE protease [96]. Crystal structures of the AE protease indicate that the flap hinge 
region of the protease is less flexible when compared to clade B protease that might lead to the lower 
turnover rates observed in the AE protease. Thus, currently available data suggest that despite the fact 
that sequence variations in non-B proteases map outside the active site, they play a role in modulating 
enzymatic activity. Viruses 2010, 2                         
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In vitro studies carried out by Holguín and colleagues have shown that M36I, a polymorphism 
found  in  most  non-B  clade  proteases,  increased  viral  replicative  capacity  in  the  absence  of  drug 
pressure while both K20I and M36I increased viral replication under drug pressure [97]. This suggests 
that  the  replicative  advantage  resulting  from  sequence  polymorphisms  could  allow  non-B  clade 
variants to spread even under drug pressure. 
Table 3. Protease positions that differ between HIV-1 clades. The line highlighted in orange 
shows amino acid substitutions that are associated with inhibitor resistance in clade B. 
Position  10  12  13  14  15  20  35  36  41  57  61  69  82  89  93 
Clade B  L  T  I  K  I  K  E  M  R  R  Q  H  V  L  I 
Resistance Associated 
Mutations in clade B 
I    V      I/R  D  I          A  M  L 
Clade A1/A2  I    V  R      D  I  K  K    K    M   
Clade C    S      V      I/V  K/N      K    M  L 
Clade D  V    V          I  K             
Clade F1/F2  V/I  S      V  R  D  I/V  K  K  N      M   
Clade G  I    V  R    I  D  I  K      K  I  M   
Clade H      V      R    I  K          I   
Clade J      V  R    R    I  K    E      M   
Clade K  I        V  R    I  K          M   
CRF01_AE      V      R  D  I  K      K    M   
CRF02_AG  V/I    V  R    I    I  K      K    M   
 
Figure  4.  HIV-1  protease  is  a  homodimer  with  the  catalytic  active  site  formed  at  the 
dimeric interface. The majority of residues that differ between various HIV-1 clades map 
to positions that are outside the active site. Red spheres represent amino acid positions and 
are indicated only on one monomer for clarity.  
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Binding studies carried out on clade A, C and G by Velazquez-Campoy and colleagues [95] and on 
CRF01_AE by Bandaranayake and colleagues [96] show that the wild type non-B clade proteases have 
an inherent weaker affinity for a number of currently available FDA approved PIs. Though these 
observations  are indicative that background polymorphisms  observed in non-B clade protease can 
affect inhibitor binding, clinical data suggest that currently available PIs can be just as effective against 
non-B clade variants as they are against clade B. However, the weaker affinity for inhibitors observed 
may make resistance easier to occur for non-B clade viruses against the current regime of PIs. This 
idea has been further strengthened by the observation of altered PI resistance pathways in some non-B 
clade proteases. Two distinct examples of altered resistance pathways in non-B clade variants have 
been in clade C, which develops L90M, and in CRF01_AE, which develops N88S, in response to NFV 
therapy whereas clade B develops D30N, N88D [98,99]. Work carried out on CRF01_AE suggests that 
the protease has an inherent weaker affinity for NFV and thus, the reduced affinity for NFV might 
allow the CRF01_AE protease to confer resistance through N88S, non-active site mutation, whereas 
clade B protease which has a higher affinity for NFV requires a combination of an active site and 
non active site mutations, D30N and N88D, in order to effectively disrupt NFV binding. 
While currently available PIs are highly effective in treating all clades, different clades might vary 
in how they respond to PI therapy. Resistance to PIs remains to be a major challenge in the effective 
treatment of HIV-1 and becomes even more relevant in geographic locations where administering 
optimal treatment regimens is difficult. Given that non-B clade HIV-1 variants are more prevalent 
across the world continued studies on non-B clade proteases are important to elucidate how sequence 
variations influence protease activity and the emergence of resistance mutations. Such studies would 
add  to  our  current  understanding  of  drug  resistance  and  help  formulate  effective  global 
treatment strategies. 
5. The Atomic Energetics of Drug Resistance  
At the roots of the molecular basis for drug resistance are the alterations in the atomic interactions 
between the PI and the resistant variant of HIV-1 protease. Free energy calculation and decomposition 
techniques  are  providing  new  insights  into  protein-ligand  interactions  [100–106].  Specifically,  the 
MM-PB/GBSA method [107,108] has been applied in several cases to study the molecular mechanism 
of HIV-1 protease drug resistance [109–112]. Compared to the classic free energy perturbation and 
thermodynamic  integration  methods  [100,102,113,114],  MM-PB/GBSA  is  computationally  less 
demanding and a more practical solution for scanning the chemical compound library to discover lead 
compounds  for  potential  new  inhibitors  [115].  The  MM-PB/GBSA  method  combines  molecular 
mechanism energies and solvation energies to estimate the absolute protein-ligand binding energy, 
allowing for the elucidation of which interactions contribute the most to the binding energy. Most of 
the interactions are calculated by the atom pairs allowing decomposition of the interaction energy to 
the residues of the protease or the functional groups of inhibitors [116,117]. Such decomposition helps 
to  elucidate  the  protease  drug  resistance  mechanism  on  an  atomic  level  and  generates  valuable 
suggestions on modification of the current inhibitors for improvement. 
Wang et al. [111] calculated the binding energy between the wild-type protease and the inhibitors 
APV, SQV, RTV, IDV, NFV and a substrate of eight amino acid residues. By comparing energy Viruses 2010, 2                         
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profiles and the differences at each protease residue, it was suggested that the drug resistant mutations 
are more likely to occur at protease residues that  interact more favorably with inhibitors than the 
substrate. They proposed that a strategy for new inhibitor design is to develop compounds that interact 
most  favorably  with  the  well  conserved  protease  residues.  By  considering  a  residue’s  energy 
contribution  to  the  binding  and  the  site’s  sequence  variability,  Wang  et  al.  defined  an  empirical 
parameter to identify the drug resistant mutations. In a study of protease binding with seven cyclic 
ureas [118], Mardis et al. reproduced the U-shaped trend of binding free energy as  a function of 
aliphatic chain length of the inhibitors. Their results also demonstrated that in treating the desolvated 
system such as the protein binding site, the finite difference Poisson-Boltzmann model [119] are more 
accurate  than  the  generalized  Born  method.  Recently,  Hou  et  al.  calculated  the  binding  affinities 
between  APV,  TMC-126,  DRV  (with  the  WT  protease  and  a  multi-drug  resistant  variant 
(V82F/I84V) [110]. Stoica et al. calculated the binding affinities between SQV with wild-type protease 
and three different drug resistant variants (G48V, L90M, G48V/L90M) [109]. Cai et al. calculated the 
binding  affinities  between  DRV  with  wild-type  protease  and  two  multi-drug  resistant  variants 
(L10I/G48V/I54V/V82A, V82T/I84V) [112]. The largest uncertainty came from the evaluation of the 
vibrational entropy. Hou et al. [110] showed that by excluding the entropy terms, the predicted binding 
free energies were in better correlation with the experimental energies. In these applications of the 
MM-PB/GBSA methods to the energetic features of protease binding with inhibitors, the predicted 
absolute binding free energy were in good agreement with the experimental results. They predicted the 
ranking of the binding affinities correctly. The more rigorous thermodynamic integrations method 
showed better prediction on the relative binding energy [112].  
Overall, by free energy decomposition analysis, the drug-resistant mutations were found to distort 
the geometry of the binding site and hence weakened the binding affinity of the inhibitors [110,112]. 
Van der Waals interaction has been found to have the biggest contribution to the protease-inhibitor 
binding affinity [109–112]. Modification of current inhibitors to design more robust inhibitors can be 
attained by evaluating changes in van der Waals interaction energy between the protease and each 
atom of the inhibitors [112]. The electrostatic energy becomes less important than the van der Waals 
because a more favorable coulombic interaction was usually associated with a higher penalty for the 
solvation energy [109–112]. Charge optimization studies have been carried out to find the best balance 
between the coulombic interaction energy and the polar solvation energy to generate compounds with 
highest electrostatic interactions energy with the protease [120–122]. 
6. Incorporating the Substrate Envelope Constraint in Structure Based Drug Design  
Developing robust HIV-1 PIs that avoid drug resistance has proven a challenging task, and the 
substrate envelope hypothesis provides an approach to solving this problem. A survey of five approved 
drugs using quantitative measures of the bound inhibitor outside the substrate envelope indicated that 
the exterior volume of the inhibitors correlated with the loss of affinity to mutant proteases [123].  
A recent study of the inhibitor R01 suggested that individual mutations did not confer drug resistance, 
but when multiple sites protrude beyond the envelope collectively, resistance may occur [124]. The 
drug DRV, which is structurally similar to APV, demonstrated improved potency with the resistant Viruses 2010, 2                         
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mutants which is attributed to both DRV’s high binding affinity and that DRV lies within the substrate 
envelope [39]. 
The ability of the substrate envelope to correlate with resistance mutations prompted the use of 
substrate  envelope  constraints  in  the  design  of  new  inhibitors  [24,29,35,125,126].  Inhibitors  were 
designed  by  varying  different  groups  on  the  hydroxyethylamine  scaffold  using  three  different 
methodologies:  Two  computational  methods  incorporated  structural  constraints  of  the  substrate 
envelope as an a priori consideration during the design stage of the inhibitors while the third method, 
structure activity relationship (SAR), did not include the substrate envelope constraint explicitly in its 
design.  The  first  computational  design  [126]  based  on  optimized  docking  resulted  in  two  good 
candidates exhibiting flat affinity profiles against multi-drug resistant mutants. But these inhibitors have 
binding  affinity  in  the  nM  range.  The  second  computational  study  systematically  explored  the 
combinatorial space for three constituent R groups on the hydroxyethylamine scaffold [29] in two rounds 
of inverse drug design, synthesis, testing, and retrospective structural analysis. The first round produced 
compounds with Ki in the range of 26 M–30 nM, which was improved to Ki of 4.1 nM–14 pM in the 
second  round  compounds.  Majority  of  these  inhibitors,  whether  they  are  nanomolar  or  picomolar 
inhibitors,  have  flatter  resistance  profiles  against  drug  resistant  variants.  Although  the  inhibitors 
designed using SAR approach [125] resulted in inhibitors with picomolar affinity to the wild-type 
protease they all lose significant affinity while binding to the drug resistant protease variants. These 
studies validated the use of the substrate envelope hypothesis [35] for the development of therapeutics 
with low susceptibility to resistance mutations in HIV-1 protease and have yielded several leads for 
potential new drugs. 
Application of the substrate envelope hypothesis to development of therapeutics to other quickly 
evolving drug targets is beginning to emerge. In a recent study [127], the hypothesis has been applied 
to five prospective drug targets from a diverse set of diseases, and the volume of inhibitors protruding 
beyond  the  native  substrate  specified  envelope  correlates  with  average  mutation  sensitivity.  This 
suggests that inhibitor design for these enzymes would benefit from a similar reverse engineering 
strategy as was implemented in the case of HIV-1 protease. The substrate envelope model has also 
been applied in the development of tenofovir, a reverse transcriptase inhibitor [128]. Similar to the 
case of HIV-1 protease, the drugs AZT and 3TC protrude beyond the consensus volume, creating an 
opportunity for the reverse transcriptase to develop resistant mutations. The newer drug, lacking such 
protrusions, is expected to evade resistance mutations as an improvement over its predecessors. Thus 
the substrate envelope hypothesis appears to be a valid general strategy for avoiding drug resistance. 
7. Conclusions  
Drug resistance in HIV protease is a subtle change in the balance of recognition events between the 
relative affinity of the HIV protease to bind inhibitors and its ability to bind and cleave substrates. 
Viral maturation involves the cleavage of Gag and Gag-Pro-Pol polyproteins by the viral protease in a 
complex, interdependent, and order-specific series of recognition and processing events. Mutations 
that confer resistance while balancing viral fitness have long been identified, both within and outside 
the active site of the enzyme, although their direct mechanism of action is not always well understood. 
Most changes confer resistance not only by altering a direct contact with a protease inhibitor, but also Viruses 2010, 2                         
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by  conferring  subtle  changes  in  the  structure  and  energetics  throughout  the  active  site.  As  many 
mutations occur simultaneously in complex combinations within a single protease variant, they are 
most likely altering both the structure and dynamics of this enzyme. Recent data also implicate that 
mutations at the protease cleavage sites as well as remote sites within Gag contribute to HIV protease 
drug resistance, possibly without altering viral fitness. The mechanism by which these changes confer 
resistance is likely an alteration in the balance of recognition events of the entire viral system and how 
the virus interacts within the host cell. Subtle changes between viral clades also alter this balance. 
Taken  together,  all  these  changes  necessitate  taking  a  comprehensive  systems  approach  to 
understanding  the  molecular  basis  for  drug  resistance  in  the  highly  interdependent  molecular 
system of HIV. 
HIV-1 protease, with its ability to recognize and cleave diverse substrate sequences, has proved to 
be a resilient drug target.  If targeted optimally in a manner that is evolutionarily constrained, the 
protease may be less susceptible to resistance. The substrate envelope hypothesis described a structure 
based drug design approach that decreases the probability of drug resistance by understanding the 
functional complexes of the HIV protease bound to its cleavage sites. The substrate envelope was then 
used  as  an  added  constraint  in  optimizing  existing  inhibitor  scaffolds  and  designing  novel  robust 
inhibitors. Other strategies, such as  focusing on main chain interactions, also may lead to similar 
results. A robust inhibitor is one that successfully inhibits a resilient target and does not quickly lose 
effectiveness due to resistance. Such an inhibitor may bind only to critical regions within the target that 
would be essential for function and thus intolerant to change. Of the currently prescribed PIs, DRV is 
the closest to being such a robust inhibitor. However, with the continuous evolution of HIV strains, 
development of other potent and robust HIV-1 protease inhibitors is highly warranted. In addition to 
drug resistance, other factors such as bioavailability, in vivo stability, and toxicity must also be taken 
into consideration when selecting a drug candidate for development.  
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